<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00476242</url>
  </required_header>
  <id_info>
    <org_study_id>#5936R R01 DA015822-01</org_study_id>
    <secondary_id>R01DA015822</secondary_id>
    <nct_id>NCT00476242</nct_id>
    <nct_alias>NCT00126711</nct_alias>
  </id_info>
  <brief_title>Memantine as a Supplement to Naltrexone in Treating Heroin Dependence</brief_title>
  <acronym>NAMHS</acronym>
  <official_title>Placebo Controlled Study of Memantine as an Adjunct to Naltrexone in the Treatment of Opioid Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective participants will undergo a screening process at the clinic to determine
      eligibility. After screening, eligible patients will complete an 8-day inpatient
      detoxification, followed by a 12-week outpatient phase. Patients will be randomly assigned to
      one of two conditions (1) Naltrexone + Placebo; (2) Naltrexone + Memantine 20 mg bid.
      Long-acting, injectable form of naltrexone (Vivitrol) will be administered once per month
      (the total of three injections) while memantine or placebo will be taken daily. In addition,
      patients will receive twice weekly psychosocial intervention that will include motivational
      interviewing and cognitive-behavioral relapse prevention. The outpatient treatment will also
      consist of 3 weekly visits to the clinic in which patients will receive counseling to help
      maintain abstinence and improve compliance with study medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the proposed trial heroin-dependent patients undergoing detoxification will be randomly
      assigned to one of two conditions (1) Naltrexone + Placebo; (2) Naltrexone + Memantine 20 mg
      bid. Long-acting, injectable form of naltrexone (Vivitrol) will be administered once per
      month (the total of three injections) while memantine or placebo will be taken daily. In
      addition, patients will receive twice weekly psychosocial intervention that will include
      motivational interviewing and cognitive-behavioral relapse prevention. The goal of
      psychosocial intervention is to improve compliance with medication and maintain abstinence. A
      double-blind trial will last twelve weeks with assessments at baseline and at each
      appointment three times per week. After the completion of a double-blind study (experimental
      phase), participants will continue open label treatment with Vivitrol and therapy for
      additional three months (study extension phase). Repeated assessments will also be completed
      one, two, and three months following the end of double-blind treatment. For the experimental
      phase of the study, the primary aim is to test the efficacy of memantine in reducing early
      attrition and improving outcome in opioid-dependent individuals maintained on naltrexone and
      primary outcome measures will be retention in treatment by the end of the study and heroin
      abstinence.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opiate Use Measured by Urine Toxicology Results</measure>
    <time_frame>3x/week during 12 weeks of the trial or study participation</time_frame>
    <description>Opiate use was qualified by the number of opiate positive urine results.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retention in Treatment The Primary Outcome Measure Will be the Dichotomous Measure Retention in Treatment (Whether the Patient Completes the 12 Week Trial, Yes/no).</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opiate Craving Based on Heroin Craving Scale</measure>
    <time_frame>measured daily for 12 weeks of study or length of participation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Opioid Dependence</condition>
  <condition>Heroin Dependence</condition>
  <arm_group>
    <arm_group_label>Memantine and Vivitrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intramuscular injection of Vivitrol 380 mg and 20 mg bid Memantine (PO)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo and Vivitrol</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intramuscular injection of Vivitrol 380 mg and Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vivitrol</intervention_name>
    <description>intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)</description>
    <arm_group_label>Memantine and Vivitrol</arm_group_label>
    <arm_group_label>Placebo and Vivitrol</arm_group_label>
    <other_name>intramuscular injection of Vivitrol 380 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>memantine</intervention_name>
    <description>Memantine will be given in two divided doses, starting with the second day of the naltrexone induction, with the target doses of 40 mg/day (or the maximum tolerated dose), for a total of twelve weeks of medication treatment.</description>
    <arm_group_label>Memantine and Vivitrol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult, aged 18-60.

          2. Meets Diagnostic and Statistical Manual IV (DSM-IV) criteria for current opiate
             dependence disorder of at least six months duration, supported by a positive urine for
             opiates and a positive naloxone challenge test if the diagnosis is unclear.

          3. Able to give informed consent.

        Exclusion Criteria:

          1. Pregnancy, lactation, or failure in a sexually active woman to use adequate
             contraceptive methods.

          2. Active medical illness which might make participation hazardous, such as untreated
             hypertension, acute hepatitis with serum glutamic oxaloacetic transaminase or serum
             glutamic-pyruvic transaminase levels &gt;2 times normal, unstable diabetes, chronic
             organic mental disorder (e.g., AIDS dementia).

          3. Active psychiatric disorder which might interfere with participation or make
             participation hazardous, including DSM-IV schizophrenia, bipolar disorder with mania
             or psychosis, and depressive disorder with suicide risk or 1 or more suicide attempts
             within the past year.

          4. History of allergic reaction to buprenorphine, naloxone, memantine, naltrexone,
             clonidine, or clonazepam.

          5. Currently prescribed or regularly taking opiates for chronic pain or medical illness.

          6. Current participation in another intensive psychotherapy or substance abuse treatment
             program or currently prescribed psychotropic medications.

          7. Current participation in a methadone maintenance treatment program and/or regular use
             of illicit methadone (&gt;30 mg per week).

          8. History of accidental drug overdose in the last three years or any other significant
             history of overdose following detoxification defined as an episode of opioid-induced
             unconsciousness or incapacitation, whether or not medical treatment was sought or
             received.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Bisaga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>STARS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stars.columbia.edu</url>
    <description>stars website</description>
  </link>
  <results_reference>
    <citation>Bisaga A, Sullivan MA, Cheng WY, Carpenter KM, Mariani JJ, Levin FR, Raby WN, Nunes EV. A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence. Drug Alcohol Depend. 2011 Dec 1;119(1-2):e23-9. doi: 10.1016/j.drugalcdep.2011.05.019. Epub 2011 Jun 28.</citation>
    <PMID>21715107</PMID>
  </results_reference>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2007</study_first_submitted>
  <study_first_submitted_qc>May 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2007</study_first_posted>
  <results_first_submitted>April 9, 2014</results_first_submitted>
  <results_first_submitted_qc>June 4, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 4, 2014</results_first_posted>
  <last_update_submitted>June 4, 2014</last_update_submitted>
  <last_update_submitted_qc>June 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heroin abuse</keyword>
  <keyword>opiate abuse</keyword>
  <keyword>opioid dependence</keyword>
  <keyword>naltrexone</keyword>
  <keyword>memantine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Heroin Dependence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Memantine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>27 participants dropped during the inpatient detoxification, therefore only 55 participants were randomized out of the 82 total enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo and Vivitrol</title>
          <description>Participants treated with placebo capsules and Vivitrol.</description>
        </group>
        <group group_id="P2">
          <title>Memantine and Vivitrol</title>
          <description>Participants treated with memantine 40 mg/d capsules and Vivitrol.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Memantine and Vivitrol</title>
          <description>intramuscular injection of Vivitrol 380 mg and 20 mg bid Memantine (PO)
Vivitrol: intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)
memantine: Memantine will be given in two divided doses, starting with the second day of the naltrexone induction, with the target doses of 40 mg/day (or the maximum tolerated dose), for a total of twelve weeks of medication treatment.</description>
        </group>
        <group group_id="B2">
          <title>Placebo and Vivitrol</title>
          <description>intramuscular injection of Vivitrol 380 mg and Placebo
Vivitrol: intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.7" spread="12.0"/>
                    <measurement group_id="B2" value="39.0" spread="11.5"/>
                    <measurement group_id="B3" value="39.4" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Opiate Use Measured by Urine Toxicology Results</title>
        <description>Opiate use was qualified by the number of opiate positive urine results.</description>
        <time_frame>3x/week during 12 weeks of the trial or study participation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Memantine and Vivitrol</title>
            <description>intramuscular injection of Vivitrol 380 mg and 20 mg bid Memantine (PO)
Vivitrol: intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)
memantine: Memantine will be given in two divided doses, starting with the second day of the naltrexone induction, with the target doses of 40 mg/day (or the maximum tolerated dose), for a total of twelve weeks of medication treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Vivitrol</title>
            <description>intramuscular injection of Vivitrol 380 mg and Placebo
Vivitrol: intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)</description>
          </group>
        </group_list>
        <measure>
          <title>Opiate Use Measured by Urine Toxicology Results</title>
          <description>Opiate use was qualified by the number of opiate positive urine results.</description>
          <units>Percent of total urine samples</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="3" upper_limit="40"/>
                    <measurement group_id="O2" value="10" lower_limit="0" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Retention in Treatment The Primary Outcome Measure Will be the Dichotomous Measure Retention in Treatment (Whether the Patient Completes the 12 Week Trial, Yes/no).</title>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Memantine and Vivitrol</title>
            <description>intramuscular injection of Vivitrol 380 mg and 20 mg bid Memantine (PO)
Vivitrol: intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)
memantine: Memantine will be given in two divided doses, starting with the second day of the naltrexone induction, with the target doses of 40 mg/day (or the maximum tolerated dose), for a total of twelve weeks of medication treatment.</description>
          </group>
          <group group_id="O2">
            <title>Placebo and Vivitrol</title>
            <description>intramuscular injection of Vivitrol 380 mg and Placebo
Vivitrol: intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)</description>
          </group>
        </group_list>
        <measure>
          <title>Retention in Treatment The Primary Outcome Measure Will be the Dichotomous Measure Retention in Treatment (Whether the Patient Completes the 12 Week Trial, Yes/no).</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.047</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opiate Craving Based on Heroin Craving Scale</title>
        <time_frame>measured daily for 12 weeks of study or length of participation</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Memantine and Vivitrol</title>
          <description>intramuscular injection of Vivitrol 380 mg and 20 mg bid Memantine (PO)
Vivitrol: intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)
memantine: Memantine will be given in two divided doses, starting with the second day of the naltrexone induction, with the target doses of 40 mg/day (or the maximum tolerated dose), for a total of twelve weeks of medication treatment.</description>
        </group>
        <group group_id="E2">
          <title>Placebo and Vivitrol</title>
          <description>intramuscular injection of Vivitrol 380 mg and Placebo
Vivitrol: intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric worsening</sub_title>
                <description>The participant attended two outpatient visits, and was removed from the study due to psychiatric worsening (irritability, insomnia, and disorganized thinking).</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="28"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Mood changes</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Increased/decreased appetite</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Fatigue/drowsiness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Body Aches</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>GI Distress</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Sweating/chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Faintness/dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adam Bisaga</name_or_title>
      <organization>NYS Psychiatric Institute</organization>
      <phone>646-774-6155</phone>
      <email>amb107@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

